Patents Examined by Jed A Kucharczk
  • Patent number: 12012396
    Abstract: The present disclosure relates to the crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide and methods of making the same. The crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide is useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.
    Type: Grant
    Filed: August 2, 2023
    Date of Patent: June 18, 2024
    Assignee: Viracta Subsidiary, Inc.
    Inventors: Xiaohu Deng, Wanping Mai, Robert C. McRae, Biljana Nadjsombati
  • Patent number: 11986476
    Abstract: Compounds for treating tuberculosis and, particularly, anti-tubercular compounds that are (6-methyl-4-substitutedphenyl-2-oxo/thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)(piperidin-1-yl)methanones and their use as anti-tubercular agents are provided.
    Type: Grant
    Filed: September 13, 2023
    Date of Patent: May 21, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Katharigatta N. Venugopala, Keshab M. Bairagi, Pran Kishore Deb, Melendran Pillay, Mohamed A. Morsy, Susanta K. Nayak, Sandeep Chandrashekharappa, Osama I. Alwassil
  • Patent number: 11981694
    Abstract: Disclosed herein are acyclic thiol prodrugs, and pharmaceutical compositions thereof. The prodrugs and pharmaceutical compositions thereof may be used to treat or prevent medical disorders such as, for example cystinosis, cystinuria, cancer neurodegenerative disease, Parkinson's disease, Huntington's disease, malaria, nonalcoholic fatty liver disease, radiation poisoning, arsenic poisoning, radioprotection, Wilson's disease or rheumatoid arthritis.
    Type: Grant
    Filed: December 28, 2022
    Date of Patent: May 14, 2024
    Assignee: Lilac Therapeutics, Inc.
    Inventors: Manoj Chandrasinhji Desai, Siva R. Kamma
  • Patent number: 11976065
    Abstract: The invention relates to novel crystalline forms of imiquimod formed with ferulic acid, acetic acid, coumaric acid, citric acid, or tartaric acid, to methods of making these cocrystals, and to compositions containing the cocrystals.
    Type: Grant
    Filed: June 23, 2021
    Date of Patent: May 7, 2024
    Assignee: CELISTA PHARM ACEUTICALS LLC
    Inventor: Yogesh Dandiker
  • Patent number: 11964938
    Abstract: A compound of the formula (I) wherein R represents a straight or branched, primary or secondary acyclic hydrocarbyl C3-C15 group, which can be saturated or unsaturated, or a straight or branched, primary or secondary acyclic hydrocarbyl C3-C15 group, which can be saturated or unsaturated and wherein one or more of hydrogen atoms is replaced with fluorine atom; X represents hydrogen atom or halogen atom, and * denotes chiral center, and salts thereof. The compound is useful for the treatment of diseases mediated by GPR40, in particular type II diabetes.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: April 23, 2024
    Assignee: CELON PHARMA S.A.
    Inventors: Mateusz Mach, Radoslaw Dzida, Damian Smuga, Filip Stelmach, Mikolaj Matloka, Katarzyna Bazydlo, Krzysztof Dubiel, Maciej Wieczorek, Jerzy Pieczykolan
  • Patent number: 11958806
    Abstract: An object is to provide a method for easily producing maleimide (MI) in which trace amounts of residual acid components as impurities in a crude MI are efficiently reduced, that is, the acid value is sufficiently reduced. <1> A method for producing purified MI, comprising reducing an acid value of crude MI by 50% or more, by adding carbodiimide (CDI) to a solution comprising the crude MI to react an acid component in the crude MI with the CDI. <2> The method for producing purified MI, comprising adding 0.5% by mass or more and 8% by mass or less of the CDI with respect to a mass of the crude MI for reaction. <3> The method for producing purified MI, wherein the CDI is N,N?-diisopropyl carbodiimide (DIC). <4> The method for producing purified MI, comprising removing a urea derivative of the CDI (CDI-U) by-produced when reacting the acid component in the crude MI with the CDI.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: April 16, 2024
    Assignee: UNITIKA LTD.
    Inventors: Yuki Yamada, Tatsuya Morikita, Yosuke Sugimoto, Takeshi Yoshida, Akira Shigeta, Yoshiaki Echigo
  • Patent number: 11951100
    Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for the treatment of retinal binding protein (RBP4) related diseases, such as macular degeneration and the like.
    Type: Grant
    Filed: September 1, 2023
    Date of Patent: April 9, 2024
    Assignee: Belite Bio, LLC
    Inventors: Yu-Hsin Tom Lin, Cheng-Chi Irene Wang
  • Patent number: 11939330
    Abstract: Novel pyrido[3,4-b]indole-6-carboxylic acid compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrido[3,4-b]indole-6-carboxylic acid compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.
    Type: Grant
    Filed: August 25, 2023
    Date of Patent: March 26, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Christophe Tratrat, Michelyne Haroun
  • Patent number: 11932616
    Abstract: The invention is directed to a process for the ring-opening of a cycloadduct obtainable from a reaction of a furanic compound and a diene, said process comprising contacting the cycloadduct with an acidic mixture comprising sulfuric acid and an activating agent to obtain a ring-opened product. The present invention is particularly directed a continuous process.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: March 19, 2024
    Assignee: Nederlandse Organisatie voor toegepast-natuurwetenschappelijk onderzoek TNO
    Inventors: Marc Crockatt, Johan Urbanus
  • Patent number: 11912706
    Abstract: The present invention relates to novel solid crystalline form of N-methyl-2-(4-methyl-1,4-diazepan-1-yl)benzo [4,5]imidazo[1,2-a][1,8]naphthyridine-6-carbaxomide, processes for the preparation thereof, compositions thereof and method of use thereof.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: February 27, 2024
    Assignee: PIMERA, INC.
    Inventor: Mustapha Haddach
  • Patent number: 11912701
    Abstract: The invention relates to compounds of formula (I) which are inhibitors of MKK4 (mitogen-activated protein kinase kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The compounds selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7. (I), wherein Rx, Ry, Rz and Rzz are selected from: a) Rx and Ry are F and Rz and Rzz are H; b) Rx, Ry and Rzz are independently halogen and Rz is H; c) Rx Rz and Rzz are independently halogen and Ry is H; and d) Rx Ry and Rz are independently halogen and Rzz is H.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: February 27, 2024
    Assignee: HepaRegeniX GmbH
    Inventors: Wolfgang Albrecht, Stefan Laufer, Roland Selig, Phillip Klövekorn, Bent Präfke
  • Patent number: 11905231
    Abstract: The present disclosure relates to solid forms and salts, crystalline and otherwise, of (E)-2-[[3-(3-methoxy-4-propargyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid and pharmaceutical compositions comprising same. The use of such solid forms, salts, and pharmaceutical compositions, for treating, preventing, or ameliorating diseases or conditions associated with fibrosis, inflammation and/or proliferation are disclosed.
    Type: Grant
    Filed: July 18, 2023
    Date of Patent: February 20, 2024
    Assignee: Certa Therapeutics Pty Ltd
    Inventors: Darren James Kelly, Gareth Rhys Lewis, Lorna Helen Mitchell
  • Patent number: 11872221
    Abstract: Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of an untreated or treatment-resistant diabetes with a glucokinase activator, optionally in combination with a dipeptidyl peptidase-4 inhibitor.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: January 16, 2024
    Assignee: HUA Medicine (Shanghai) Ltd.
    Inventors: Li Chen, Shuang Ren, Jiayi Zhang
  • Patent number: 11866452
    Abstract: A biphenyl compound represented by formula (I), a preparation method therefor and an application thereof. The present invention also relates to a pharmaceutical composition that comprises the compound as an active ingredient. The compound is a novel small molecule immunomodulator having excellent oral absorption features and can be used for treating and/or preventing various immunity-related diseases.
    Type: Grant
    Filed: October 28, 2021
    Date of Patent: January 9, 2024
    Assignee: Shenzhen Chipscreen Biosciences Co., Ltd.
    Inventors: Qianjiao Yang, Song Shan, Lijun Xin, Desi Pan, Xiaoliang Wang, Yonglian Song, Yu Zhang, Huiyun Huang, Qi Wei, Zhibin Li, Xianping Lu
  • Patent number: 11865079
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a purified compound described herein.
    Type: Grant
    Filed: February 10, 2022
    Date of Patent: January 9, 2024
    Assignee: Servier Pharmaceuticals LLC
    Inventor: Chandra Agarwal Prakash
  • Patent number: 11851419
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Grant
    Filed: November 18, 2021
    Date of Patent: December 26, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Gediminas J. Brizgys, James S. Cassidy, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, James G. Taylor, Nathan E. Wright, Zheng-Yu Yang
  • Patent number: 11851405
    Abstract: A dialkyl carbonate is prepared by reacting urea with an alkyl monohydric alcohol at 70° C. to 150° C. under normal pressure or reduced pressure. The reaction is conducted for 6 h to 30 h under stirring and reflux, with one or more of magnesium, calcium, aluminum, chromium, manganese, iron, cobalt, nickel, copper and zinc as a primary catalyst and one or more compounds including an electron-donating nitrogen, phosphonis, oxygen or sulfur atom as a catalyst promoter. The dialkyl carbonate is prepared under low reaction temperature and normal pressure or reduced pressure, with high selectivity and high yield. With simple operations, high safety and low cost for the process, the method has prominent industrial application prospects.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: December 26, 2023
    Inventors: Yongcheng Lei, Yongzhong Lei
  • Patent number: 11844758
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Grant
    Filed: January 26, 2021
    Date of Patent: December 19, 2023
    Assignee: Servier Pharmaceuticals LLC
    Inventors: Zenon Konteatis, Janeta Popovici-Muller, Jeremy Travins, Robert Zahler, Zhenwei Cai, Ding Zhou
  • Patent number: 11844784
    Abstract: Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, and which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine, or pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.
    Type: Grant
    Filed: June 2, 2023
    Date of Patent: December 19, 2023
    Assignee: SLAYBACK PHARMA LLC
    Inventors: Harish Govindaraja Setty Chinnari, Somashekhar Battini, Sumitra Ashokkumar Pillai, Lourdu Chinnu Thippabattuni, Satheesh Balasubramanian
  • Patent number: 11840535
    Abstract: Provided is an alkynyl(hetero)aromatic compound having an inhibitory effect to protein tyrosine kinase, a pharmaceutical composition comprising same, preparation and usage thereof. Specifically, disclosed is an alkynyl(hetero)aromatic compound as shown in formula (I), wherein rings A, R1, R2, R3, R4, R5, L, and B are defined in the description, a pharmaceutically acceptable salt, a stereoisomer, a solvate, a hydrate, a crystal form, a prodrug or an isotopic variant thereof. The compound can be used for treating and/or preventing protein tyrosine kinase-related diseases, such as anti-tumor.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: December 12, 2023
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Qingfeng Xing